Shares of AbbVie (ABBV) lost ~7% on Wednesday after the Chicago-based pharma giant posted better-than-expected Q4 2025 ...
Investor's Business Daily on MSN
AbbVie pummeled after delivering a fourth-quarter beat — on the back of Humira
Investors pummeled AbbVie stock Wednesday after the company delivered a fourth-quarter sales beat, thanks to Humira.
Humira (adalimumab) is a biologic medication used to treat several chronic inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, and plaque psoriasis. For years, it has been one of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results